Philogen S.p.A.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Philogen S.p.A. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Philogen S.p.A.: 7 sponsored US clinical trials, 4 recruiting.
Philogen S.p.A. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma Stage IIID, with 1 trials.
Upper-quartile sponsor footprint
Philogen S.p.A. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
NCT07227350
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
NCT06284590
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
NCT06336291
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
NCT04032964
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Philogen S.p.A. pipeline
4 recruiting of 7 indexed (57% open).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Melanoma Stage IIID (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Philogen S.p.A.: open-pipeline peers nationwide
Peers matched on 7 registered trials and 57% open enrollment, not the therapeutic-area sidebar.
Philogen S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 57% open enrollment (± trial volume)
- Alimentiv · 57% recruiting · 7 trials
- Aura Biosciences · 57% recruiting · 7 trials
- BicycleTx Limited · 57% recruiting · 7 trials
- Binghamton University · 57% recruiting · 7 trials
Related
What to do with this Philogen S.p.A. page
7 registered trials is a research-attention snapshot, not an endorsement of Philogen S.p.A. or any single study.
- 4 of Philogen S.p.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma Stage IIID is the condition Philogen S.p.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma Stage IIID trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Philogen S.p.A. pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.